[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [2] HESKETH R L, ZHU A X, OKLU R.Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?[J]. Diagn Interv Radiol, 2015, 21(1): 78-84. [3] HESKETH R L, ZHU A X, OKLU R.Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care?[J]. Am J Clin Oncol, 2015, 38(4): 431-436. [4] CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [5] VILLANUEVA A.Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. [6] MARTIN J, PETRILLO A, SMYTH E C, et al.Colorectal liver metastases: Current management and future perspectives[J]. World J Clin Oncol, 2020, 11(10): 761-808. [7] CHAUHAN N, MULCAHY M F, SALEM R, et al.TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial[J]. JMIR Res Protoc, 2019, 8(1): e11545. [8] ANDREWS J C, WALKER S C, ACKERMANN R J, et al.Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up[J]. J Nucl Med, 1994, 35(10): 1637-1644. [9] DANCEY J E, SHEPHERD F A, PAUL K, et al.Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres[J]. J Nucl Med, 2000, 41(10): 1673-1681. [10] HOULE S, YIP T K, SHEPHERD F A, et al.Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres[J]. Radiology, 1989, 172(3): 857-860. [11] BIEDERMAN D M, TITANO J J, TABORI N E, et al. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres[J]. J Vasc Interv Radiol, 2016, 27(6): 812-821.e812. [12] KIM H C.Radioembolization for the treatment of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2017, 23(2): 109-114. [13] SANGRO B, CARPANESE L, CIANNI R, et al.Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation[J]. Hepatology, 2011, 54(3): 868-878. [14] SALEM R, LEWANDOWSKI R, ROBERTS C, et al.Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis[J]. J Vasc Interv Radiol, 2004, 15(4): 335-345. [15] SALEM R, JOHNSON G E, KIM E, et al.Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study[J]. Hepatology, 2021. [16] MURTHY R, NUNEZ R, SZKLARUK J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations,potential complications[J]. Radiographics, 2005, 25 Suppl 1: S41-S55. [17] LEE E J, CHUNG H W, JO J H, et al.Radioembolization for the Treatment of Primary and Metastatic Liver Cancers[J]. Nucl Med Mol Imaging, 2019, 53(6): 367-373. [18] MOHAMED M, KATZ A W, TEJANI M A, et al.Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma[J]. Adv Radiat Oncol, 2016, 1(1): 35-42. [19] SHETH R A, PATEL M S, KOOTTAPPILLIL B, et al.Role of Locoregional Therapy and Predictors for Dropout in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation[J]. J Vasc Interv Radiol, 2015, 26(12): 1761-1768. [20] RIAZ A, GATES V L, ATASSI B, et al.Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization[J]. Int J Radiat Oncol Biol Phys, 2011, 79(1): 163-171. [21] VOUCHE M, HABIB A, WARD TJ, et al.Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy[J]. Hepatology, 2014, 60(1): 192-201. [22] PADIA S A, JOHNSON G E, HORTON K J, et al.Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study[J]. J Vasc Interv Radiol, 2017, 28(6): 777-785 e771. [23] SHINKAWA H, TAKEMURA S, TANAKA S, et al.Portal Vein Embolization: History and Current Indications[J]. Visc Med, 2017, 33(6): 414-417. [24] GABA R C, LEWANDOWSKI R J, KULIK L M, et al.Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization[J]. Ann Surg Oncol, 2009, 16(6): 1587-1596. [25] OKUDA K, OHNISHI K, KIMURA K, et al.Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients[J]. Gastroenterology, 1985, 89(2): 279-286. [26] KULIK L M, CARR B I, MULCAHY M F, et al.Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis[J]. Hepatology, 2008, 47(1): 71-81. [27] MEMON K, KULIK L, LEWANDOWSKI R J, et al.Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression[J]. J Hepatol, 2013, 58(1): 73-80. [28] MAZZAFERRO V, SPOSITO C, BHOORI S, et al.Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study[J]. Hepatology, 2013, 57(5): 1826-1837. [29] WANG D S, LOUIE J D, SZE D Y.Evidence-Based Integration of Yttrium-90 Radioembolization in the Contemporary Management of Hepatic Metastases from Colorectal Cancer[J]. Tech Vasc Interv Radiol, 2019, 22(2): 74-80. [30] RAVAL M, BANDE D, PILLAI AK, et al.Yttrium-90 radioembolization of hepatic metastases from colorectal cancer[J]. Front Oncol, 2014, 4: 120. [31] JEYARAJAH D R, DOYLE M B M, ESPAT N J, et al. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm[J]. J Gastrointest Oncol, 2020, 11(2): 443-460. [32] MULCAHY M F, MAHVASH A, PRACHT M, et al.Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase Ⅲ Trial[J]. J Clin Oncol, 2021: JCO2101839. [33] SALEM R, GABR A, RIAZ A, et al.Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience[J]. Hepatology, 2018, 68(4): 1429-1440. [34] CHAN K T, ALESSIO A M, JOHNSON G E, et al.Prospective Trial Using Internal Pair-Production Positron Emission Tomography to Establish the Yttrium-90 Radioembolization Dose Required for Response of Hepatocellular Carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018, 101(2): 358-365. [35] GARIN E, TSELIKAS L, GUIU B, et al.Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(1): 17-29. [36] VOGEL A, MARTINELLI E, ESMO GUIDELINES COMMITTEE, et al.Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2021, 32(6): 801-805. [37] TURGEON G A, WEICKHARDT A, AZAD A A, et al.Radiotherapy and immunotherapy: a synergistic effect in cancer care[J]. Med J Aust, 2019, 210(1): 47-53. [38] MONDINI M, LEVY A, MEZIANI L, et al.Radiotherapy-immunotherapy combinations-perspectives and challenges[J]. Mol Oncol, 2020, 14(7): 1529-1537. |